Harvard Bioscience (HBIO) to Release Quarterly Earnings on Thursday

Harvard Bioscience (NASDAQ:HBIO) is expected to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $23.10 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 8:00 AM ET.

Harvard Bioscience Stock Up 1.4%

NASDAQ HBIO opened at $0.57 on Thursday. The stock has a market capitalization of $25.65 million, a PE ratio of -0.47 and a beta of 1.51. Harvard Bioscience has a 12-month low of $0.28 and a 12-month high of $0.95. The company has a 50 day moving average price of $0.59 and a two-hundred day moving average price of $0.57.

Institutional Investors Weigh In On Harvard Bioscience

Several hedge funds have recently modified their holdings of HBIO. Bank of America Corp DE increased its position in Harvard Bioscience by 44.4% during the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after acquiring an additional 11,948 shares during the period. XTX Topco Ltd bought a new position in shares of Harvard Bioscience during the 4th quarter worth about $26,000. Goldman Sachs Group Inc. raised its position in shares of Harvard Bioscience by 291.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 37,057 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Harvard Bioscience in the fourth quarter valued at about $40,000. Finally, Jane Street Group LLC grew its position in Harvard Bioscience by 491.9% during the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 58,785 shares in the last quarter. 80.87% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HBIO shares. Zacks Research raised shares of Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. Wall Street Zen upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Harvard Bioscience currently has a consensus rating of “Hold” and a consensus price target of $2.00.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.